Basic Information
Develop novel drugs targeting metalloproteins by combining bioinorganic chemistry with medicinal chemistry. ForgeTherapeutics has pioneered a new approach for discovering metalloprotein inhibitors by focusing on the metals within enzyme active sites.
ForgeTherapeutics
--
15~50 people
January 01, 2015
Info@ForgeTherapeutics.com
Enterprise Profile
Technology